BB Biotech AG has been included in the SPI ESG Index of the SIX Swiss Exchange effective September 22, 2025. This development recognizes the investment company's sustained dedication to responsible investing practices and sustainable corporate governance frameworks. The inclusion carries substantial implications for BB Biotech's market positioning and reflects broader trends in sustainable finance.
Dr. Christian Koch, Head of BB Biotech at Bellevue Asset Management, emphasized the significance of this inclusion. The inclusion in the SPI ESG Index is an important confirmation of our commitment to sustainability, Koch stated. It also underscores our strategic focus on biotechnology companies that create financial value while making an important contribution to society. This recognition validates the company's investment philosophy, which balances financial returns with positive societal impact.
The SPI ESG Index, launched in 2021, comprises companies from the Swiss Performance Index that meet rigorous sustainability criteria as evaluated by independent sustainability agency Inrate. This index serves as a transparent benchmark for investors seeking sustainable equity investment opportunities within the Swiss market. More information about the index methodology can be found at https://www.six-group.com. The enhanced visibility among ESG-oriented investors reflects growing recognition of BB Biotech's approach to sustainable investing.
The biotechnology sector's inherent focus on healthcare innovation aligns naturally with ESG principles, particularly through developing treatments that address unmet medical needs. The recognition comes at a time when sustainable investing continues to gain momentum globally. Investors increasingly prioritize companies demonstrating strong environmental, social, and governance practices. BB Biotech's portfolio, consisting primarily of innovative drug developers headquartered in the United States and Western Europe, now benefits from this formal ESG endorsement.
As one of the world's largest investors in the biotechnology sector, BB Biotech's inclusion in the SPI ESG Index signals broader industry trends toward sustainable investment practices. The company's investment decisions are made by Bellevue Asset Management's experienced team based on extensive research, with strategic oversight from a competent Board of Directors possessing long-standing industry experience. Additional company information is available at https://www.bbbiotech.com. The index inclusion not only validates BB Biotech's existing approach but potentially enhances the long-term attractiveness of its investment portfolio.
This development underscores how biotechnology investments can simultaneously deliver financial returns and contribute to societal wellbeing through medical innovation, positioning BB Biotech favorably within the evolving landscape of sustainable finance. The formal recognition through index inclusion provides independent validation of the company's ESG credentials and may attract a broader base of investors who prioritize sustainability criteria in their investment decisions.
